After her MBA, Michal Preminger spent three years in tech, deliberately taking on diverse roles like sales and product management. This fast-paced environment provided a condensed, real-world business education that she later applied back in the biotech sector.

Ovelle's co-founders exemplify a common success pattern in biotech: one partner with profound scientific knowledge (Merrick) and another with extensive business experience (Travis). This combination covers critical aspects from research to capital raising and team building, as it's rare to find both skill sets in one person.

CEOs of ElevenLabs and Lovable argue their time at companies like Palantir and Google was essential for learning to build at scale, understand customer problems, and develop ambitious ideas. They doubt they would have succeeded starting right out of school.

Dr. Vibha Jawa's career shows a powerful strategy: learning drug development fundamentals in large companies (Amgen, Merck) and applying them in nimble startups. This cycle across different environments accelerates learning and deepens expertise in a specialized field like immunogenicity.

Daniel Lowther's journey from an autoimmunity PhD to a biomarkers director at GSK wasn't linear. He advanced by opportunistically moving into adjacent fields like brain cancer, self-taught coding, and even IT, proving a winding path can build a uniquely diverse and valuable skill set.

Unlike software startups that can "fail fast" and pivot cheaply, a single biotech clinical program costs tens of millions. This high cost of failure means the industry values experienced founders who have learned from past mistakes, a direct contrast to Silicon Valley's youth-centric culture.

Rather than viewing his long tenure at Pfizer as the final destination, Doogan frames it as a crucial learning period. This "apprenticeship" provided invaluable experience with drug development, failure, and industry dynamics, which directly enabled his later success as a biotech founder and executive.

Luba Greenwood argues that unlike in tech, many biotech CEOs lack P&L experience. In today's cash-constrained market, CEOs need to be able to build financial models and understand finance deeply to be effective, a skill she personally developed after transitioning from law and science.

Kenai CEO Nick Manusos attributes his startup success to his varied background at Abbott Labs, moving from manufacturing to sales to BD. This breadth prepared him to handle the multifaceted demands of a startup, where a leader must be a generalist who is comfortable with constant change.